首页> 外文期刊>European urology >Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status
【24h】

Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

机译:回复:基于p53状态的分子靶向辅助治疗在局部晚期膀胱尿路上皮癌中的III期研究

获取原文
获取原文并翻译 | 示例
           

摘要

Experts' summary:Retrospective evaluations had suggested that p53 dysregula-tion is prognostic and predictive of response to cytotoxic chemotherapy in bladder cancer. This phase 3 study assessed tumors from postcystectomy patients with pT1-2 NO MO bladder cancer for p53 overexpression. Mutant p53 is stabilized and detectable by immunohistochemistry, whereas wild-type p53 is quickly degraded.
机译:专家总结:回顾性评估表明,p53失调可预后并预测膀胱癌对细胞毒性化学疗法的反应。这项3期研究评估了来自pT1-2 NO MO膀胱癌的膀胱切除术后患者的肿瘤中p53的过度表达。 p53突变体可以通过免疫组织化学稳定和检测,而野生型p53则可以快速降解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号